Latest News

Aflibercept biosimilar QL1207 shows comparable efficacy to the reference drug in treating diabetic macular edema, offering a potentially affordable treatment option for those facing adherence and accessibility issues.

Experts explore the evolving role of HER2- and TROP2-targeted therapies in breast cancer treatment at SABCS 2025, highlighting ADC advancements.

FDA approves gepotidacin as a new oral treatment for uncomplicated gonorrhea, expanding options against resistant sexually transmitted infections.

Policy Needs to Catch Up to the People Behind the Counter

Latest findings presented at SABCS 2025 support trastuzumab deruxtecan's effectiveness and safety in treating HER2-positive breast cancer.

The FDA approves Flow's at-home depression treatment headset, offering a new approach to managing mental health with transcranial stimulation technology.

New research highlights the benefits of adding isatuximab to standard therapy for newly diagnosed multiple myeloma (NDMM), improving patient outcomes and quality of life.

Tucatinib enhances first-line maintenance therapy for HER2-positive metastatic breast cancer, improving progression-free survival and safety outcomes, as shown in the HER2CLIMB-05 trial.

Cell-cycle–focused CDK inhibitors offer new options for HR+/HER2– metastatic breast cancer after CDK4/6 resistance.

Asundexian shows promise in reducing ischemic stroke risk without increasing major bleeding, offering hope for secondary stroke prevention.

The FDA approved etuvetidigene autotemcel, the first gene therapy for Wiskott-Aldrich syndrome, transforming treatment options for affected patients.

The Emerging Practice Model Is Having a Moment in Popular Culture. What Is It and What Is the Role of Pharmacy?

Pharmacists debate the effectiveness and ethics of GLP-1 agonists for pediatric obesity, highlighting the need for balanced treatment approaches.

Oral SERDs and combination therapies are redefining post-CDK4/6 treatment in HR+/HER2– metastatic breast cancer.

Pharmacists explore AI's transformative potential, evaluating its applications and ensuring ethical integration to enhance patient care and pharmacy operations.

Exploratory analysis shows 1 in 4 patients maintain long-term response to ribociclib.

Teclistamab and daratumumab with hyaluronidase combination show significant efficacy in relapsed multiple myeloma (MM), potentially redefining treatment standards.

Pharmacists leverage sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve interconnected cardiovascular-kidney-metabolic (CKM) syndrome outcomes through holistic, patient-centered care.

New long-term data reveals avapritinib's impressive efficacy and safety for advanced systemic mastocytosis.

Economic factors are driving sterile injectable drug shortages, but collaborative strategies can enhance health care industry resiliency.